- Home
- EQ vs MDRR Comparison
EQ vs MDRR Comparison
Compare EQ & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- MDRR
- Stock Information
- Founded
- EQ 2017
- MDRR 2015
- Country
- EQ United States
- MDRR United States
- Employees
- EQ N/A
- MDRR N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- MDRR Real Estate Investment Trusts
- Sector
- EQ Health Care
- MDRR Real Estate
- Exchange
- EQ Nasdaq
- MDRR Nasdaq
- Market Cap
- EQ 13.1M
- MDRR 14.5M
- IPO Year
- EQ 2018
- MDRR 2018
- Fundamental
- Price
- EQ $0.93
- MDRR $10.63
- Analyst Decision
- EQ Buy
- MDRR
- Analyst Count
- EQ 3
- MDRR 0
- Target Price
- EQ $3.00
- MDRR N/A
- AVG Volume (30 Days)
- EQ 21.2M
- MDRR 708.0
- Earning Date
- EQ 08-19-2025
- MDRR 08-19-2025
- Dividend Yield
- EQ N/A
- MDRR 2.52%
- EPS Growth
- EQ N/A
- MDRR N/A
- EPS
- EQ N/A
- MDRR N/A
- Revenue
- EQ $30,406,000.00
- MDRR $9,649,145.00
- Revenue This Year
- EQ N/A
- MDRR N/A
- Revenue Next Year
- EQ N/A
- MDRR N/A
- P/E Ratio
- EQ N/A
- MDRR N/A
- Revenue Growth
- EQ N/A
- MDRR N/A
- 52 Week Low
- EQ $0.27
- MDRR $9.55
- 52 Week High
- EQ $1.50
- MDRR $15.00
- Technical
- Relative Strength Index (RSI)
- EQ 71.79
- MDRR 46.83
- Support Level
- EQ $0.46
- MDRR $10.05
- Resistance Level
- EQ $1.25
- MDRR $10.75
- Average True Range (ATR)
- EQ 0.20
- MDRR 0.18
- MACD
- EQ 0.04
- MDRR -0.03
- Stochastic Oscillator
- EQ 57.41
- MDRR 48.11
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.